Company maintains 2026 financial outlook
Third Quarter 2026 Financial Summary
Revenue of $43.3 million
Gross profit margin of 67.7%
Net income of $0.6 million and diluted earnings per share attributable to
biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our Practitioners’ patients, today announced
Continued progress in advancing strategic initiatives
Updates full-year outlook
Second Quarter 2026 Financial Highlights
Revenue of $44.2 million
Gross profit margin of 65.4%
Net loss of $(7.4) million and
biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our Practitioners’ patients, today announced
Biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company") today announced the appointment of Komal Bajaj, MD, MS, as Chief Medical Officer, effective June 1, 2026.
Dr. Bajaj is a nationally recognized physician executive,
Bret Christensen Stepping Down as CEO for Family and Personal Reasons, Remains a Director
Company Reaffirms Full Year 2026 Guidance
Biote (NASDAQ:BTMD), a leader in innovative hormone optimization and healthy aging
Sales team expansion on track and nearing targeted level
Return to procedure growth expected in second half of 2026
First Quarter 2026 Financial Highlights
Revenue of $44.9 million
Gross profit margin of
biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our Practitioners' patients, today announced the Company will
Executing efficiently on strategic priorities
Continued salesforce expansion to capture large growth opportunity
Anticipate a return to procedure revenue growth in the second half of 2026
Fourth Quarter 2025
biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading innovator advancing the healthspan of patients' lives by providing hormone replacement therapy and healthy aging solutions, today announced the Company
Continued progress against strategic priorities
Repurchased approximately one million shares of Class A common stock
Reiterates 2025 financial guidance
Third Quarter 2025 Financial Highlights
Revenue of $48.0
biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the
Q2 financial performance driven by strong dietary supplement sales and gross margin expansion
Launched corporate reorganization to increase new clinic and procedure growth
Decisive actions position Biote for
biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the
biote Corp.(NASDAQ:BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that its Board of Directors has
